Treatment of in-stent restenosis for saphenous vein grafts using intravascular brachytherapy: regulatory challenges and clinical application.
Treatment of in-stent restenosis using intravascular brachytherapy (IVBT) has been demonstrated to be successful and has become the standard of care for native coronary artery disease. Based on the current Food and Drug Administration (FDA) indications for use and the clinical demand to increase the scope of this form of therapy to include saphenous vein grafts for the Beta-Cath  System (Novoste Corporation, Norcross, Georgia), we set out to obtain institutional approval for off-label use. Identification of institutional regulatory bodies and related procedures for obtaining off-label device use was performed. Additionally, the IVBT written directive proscription and patient informed consent forms were revised to accurately administer radiation dose and to disclose the regulatory status of using IVBT for this anatomic site. While the specifics are outlined in this report, this process and the resources needed to obtain institutional approval for off-label use are indicative of that to be expected at similar institutions.
Rivard
Mark J
MJ
Department of Radiation Oncology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. mrivard@tufts-nemc.org
Zinkin
Heather D
HD
Mignano
John E
JE
Kimmelstiel
Carey D
CD
D019917:Blood Vessel Prosthesis Implantation / Q000592:standards; D001918:Brachytherapy / Q000592:standards; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000532:radiotherapy*; D006801:Humans; D007258:Informed Consent / Q000592:standards; D019275:Radiopharmaceuticals / Q000592:standards / Q000627:therapeutic use; D012308:Risk Management / Q000592:standards; D012501:Saphenous Vein / Q000528:radiation effects*; D015607:Stents / Q000592:standards; D013326:Strontium Radioisotopes / Q000592:standards / Q000627:therapeutic use; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes